Ondansetron B. Braun (Ondansetron)

Ondansetron works by selectively blocking serotonin (5‑HT3) receptors in the gastrointestinal tract and the brain’s chemoreceptor trigger zone. This inhibition stops the signaling cascade that normally triggers the vomiting reflex, thereby reducing nausea and vomiting.

The appropriate dose of ondansetron is determined by the prescribing clinician based on the patient’s age, weight, the type of treatment causing nausea, and other clinical factors. Dosing recommendations are provided in the product’s prescribing information.

Safety data for ondansetron in pregnancy and lactation are limited. Clinicians should weigh the potential benefits against possible risks and consider alternative therapies when appropriate. Pregnant or nursing patients should discuss use with their healthcare provider.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Ondansetron belongs to the 5‑HT3 antagonist class, which is particularly effective for chemotherapy‑induced nausea and postoperative vomiting. Compared with dopamine antagonists or antihistamines, ondansetron generally offers a more targeted mechanism with a lower incidence of sedation and extrapyramidal side effects.

Ondansetron B. Braun should be stored at 2‑8 °C (refrigerated). Keep the solution in its original container, protect it from light, and avoid freezing or shaking the vial. Do not use the product if it appears discolored or contains particles.

The product is supplied as an intravenous solution and is administered by slow IV injection or infusion, as directed by the prescribing clinician. Administration techniques, including infusion rate and dilution, are outlined in the product’s labeling and should be followed precisely.

Serious risks include QT interval prolongation, which can lead to cardiac arrhythmias, severe allergic reactions such as anaphylaxis, and, rarely, serotonin syndrome when combined with other serotonergic agents. Patients should be monitored for cardiac symptoms and any signs of hypersensitivity.

Ondansetron should be avoided in individuals with known hypersensitivity to the drug or any of its excipients. Caution is also advised for patients with a history of prolonged QT interval, significant cardiac disease, or those taking other medications that prolong the QT interval.